In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Primary voting starts in a matter of weeks. We’ll identify which midterm races could define 2026. Could the growth of prediction markets change the political landscape? Plus, what we got wrong in 2025 ...

Left upper quadrant (LUQ) pain stems from conditions that affect organs like your spleen, kidney, or stomach. It's best to see a doctor if your LUQ pain worsens or lasts more than 48 hours. Treatment ...

A 1966 example of the Ford GT40 MkII is heading to auction in January—and it’s not just any example of the already ultra-rare car, but the “most original” one. Eleven MkII GT40s were built, and just ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

In a scene that perfectly captures the strangeness of American politics today, President Trump, a billionaire and self-styled champion of American business (at least the ones he likes) was all smiles ...